Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 424 participants.

Also called NCT07122401

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 424 participants (planned count) (from the registry)
Sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (from the registry)
Registry
  • NCT NCT07122401
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07122401. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-30 (actual); primary completion 2026-11-26 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
Condition
Secondary Hyperparathyroidism, Chronic Kidney Disease
Intervention (Drug)
MT1013
Intervention (Drug)
Cinacalcet
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07122401
Content hash
ee59b069a9c74bec48089e0e43ab413222f571c0d33e5e324c50b98d45c5b3c6